These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12813977)

  • 1. [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
    Reblin T; Seidel D; Stein D; Görtz A; Lander T
    MMW Fortschr Med; 2003 May; 145(19):41. PubMed ID: 12813977
    [No Abstract]   [Full Text] [Related]  

  • 2. [Infarct prevention for diabetics. To lower blood sugar is not enough].
    MMW Fortschr Med; 2001 Nov; 143(46):61. PubMed ID: 11759608
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intensive therapy in type 2 diabetes. More damage than benefit?].
    Einecke D
    MMW Fortschr Med; 2008 Jun; 150(26-27):12-4. PubMed ID: 18681224
    [No Abstract]   [Full Text] [Related]  

  • 4. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
    Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
    Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
    [No Abstract]   [Full Text] [Related]  

  • 5. [Type 2 diabetes. How can the infarction risk be reduced?].
    MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921655
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1999 Aug; 41(1059):71-3. PubMed ID: 10603986
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rosiglitazone (BRL-49653)].
    Kameda N; Okuya S; Oka Y
    Nihon Rinsho; 2000 Feb; 58(2):401-4. PubMed ID: 10707565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct].
    MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856
    [No Abstract]   [Full Text] [Related]  

  • 10. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
    Dharmalingam M; Kumar P
    J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    Fisher M
    Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA; Sautter M; Van Gaal LF; Jones NP
    Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of glycemic control.
    Shahady EJ
    J Fam Pract; 2011 Sep; 60(9 Suppl):S4-6. PubMed ID: 21912776
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Sep; 22(9):288-9. PubMed ID: 10577070
    [No Abstract]   [Full Text] [Related]  

  • 17. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial.
    van Dieren S; Czernichow S; Chalmers J; Kengne AP; de Galan BE; Poulter N; Woodward M; Beulens JW; Grobbee DE; van der Schouw YT; Zoungas S
    Diabetes Obes Metab; 2012 May; 14(5):464-9. PubMed ID: 22226008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance on rosiglitazone for type 2 diabetes mellitus.
    Matthews DR
    Lancet; 2001 Feb; 357(9254):481. PubMed ID: 11273100
    [No Abstract]   [Full Text] [Related]  

  • 19. A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.
    Halimi S; Aubert JP; Fontbonne A; Guillausseau PJ; Nachit F; Bouée S; Detournay B
    Diabetes Metab; 2012 Oct; 38(4):343-51. PubMed ID: 22521038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y; Wakasugi T; Yagi K; Mabuchi H
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.